Emmaus Life Sciences Reports Quarterly Financial Results
Key Highlights
- ➤Q3 net revenue $1.9 million, down from $3.4 million year over year
- ➤Q3 net loss $4.7 million, or $0.07 per share, versus $2.1 million
- ➤Cash and equivalents $1.0 million at September 30, down from $2.1 million
- ➤Nine-month revenue $10.2 million, up from $8.6 million year over year
- ➤U.S. net revenue declined 44% after the NeoImmuneTech licensing agreement
Expert Statements
Willis Lee, Chairman and Chief Executive Officer of Emmaus Life Sciences
“Our global net revenues declined for the three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as our licensing agreement with NeoImmuneTech Inc. (NIT), became effective on May 15, 2026,”
Willis Lee, Chairman and Chief Executive Officer of Emmaus Life Sciences
“The decline was partially offset by a related reduction in our operating expenses. Management believes that the conflict in the Middle East also adversely affected net revenues in the region,”
Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2026.
“Our global net revenues declined for the three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as our licensing agreement with NeoImmuneTech Inc. (NIT), became effective on May 15, 2026,” commented Willis Lee, Chairman and Chief Executive Officer of Emmaus. “The decline was partially offset by a related reduction in our operating expenses. Management believes that the conflict in the Middle East also adversely affected net revenues in the region,” he added.
Get started
Create a free account to read the full story.
